Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AdAlta Ltd. ( (AU:1AD) ) has shared an announcement.
AdAlta Limited has completed a capital raising via a private placement, issuing 240 million fully paid ordinary shares at $0.005 per share to sophisticated investors, along with 120 million attaching options exercisable at $0.01 and expiring on 3 June 2028, and an additional 14.4 million shares and 82.2 million options to the lead manager. The company has confirmed compliance with its continuous disclosure and financial reporting obligations under the Corporations Act, enabling these securities to be traded without a prospectus, which strengthens its balance sheet and provides additional funding flexibility while potentially diluting existing shareholders but broadening its investor base.
The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Limited (ASX:1AD) is an Australia-based biotechnology company listed on the Australian Securities Exchange, developing therapeutic products using its proprietary platforms for medical and healthcare applications.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$11.48M
See more insights into 1AD stock on TipRanks’ Stock Analysis page.